Bio-Techne’s Q3 FY2026: Pharma Momentum, a 2% Revenue Dip, and an EPS Twist

Bio-Techne Corp (NASDAQ: TECH) reported its third-quarter FY2026 results for the quarter ended March 31, 2026, with GAAP EPS of $0.32 and adjusted EPS of $0.53 on net sales of $311.4 million. The company shows a 2% organic revenue decline, aided by currency tailwinds and offset by a non-recurring prior-year revenue from a held-for-sale business. The release foregrounds the numbers rather than declaring a pronounced earnings surprise, and it positions the outlook through the lens of analysts’ EPS consensus and a cautious revenue forecast for the remainder of the year.

Third Quarter Highlights

Revenue: Net sales $311.4 million, down 2% organically; foreign currency impact +2%; non-recurring held-for-sale revenue a -2% headwind.
EPS: GAAP EPS $0.32; adjusted EPS $0.53, down from $0.56 in the prior year.
Market backdrop: Large pharma led with double-digit growth for a sixth straight quarter; emerging biotech spent lagged; U.S. academic markets stabilized with low-single-digit growth.
Growth vectors: Proteomic Analysis instruments in mid-single-digit growth; Spatial Biology in mid-teens; GMP proteins excluding fast-track customers up nearly 50%.

Executive Commentary

Kim Kelderman, Bio-Techne’s President and CEO, described solid execution amid a mixed end-market environment and highlighted that large pharma continued to drive results, partially offsetting a slower biotech narrative. Kelderman added that early indicators point to a more constructive outlook as funding activity and customer purchasing realign, with Bio-Techne positioned to support durable, high-value applications across the scientific journey. It’s the kind of talk that makes you grateful for a diversified lineup even if the near-term revenue line still shows a dip.

Growth Vectors and Portfolio Mix

The company notes continued strength in the “growth vectors” of its portfolio. Growth in Proteomic Analysis tools remains in the mid-single digits, Spatial Biology shows mid-teens growth, and GMP proteins (excluding fast-track customers) approach 50% growth. Management attributes this to a mix shift toward higher-value applications and large, durable customer relationships, even as some segments within biotech lag behind.

Conference Call and Access

Bio-Techne will host its earnings conference call on May 6, 2026, at 8:00 a.m. CDT. Dial 1-800-343-4136 or international 1-203-518-9843, and reference conference ID TECHQ3. The earnings call can also be accessed via webcast at the investor relations site. A recorded rebroadcast will be available at 1-844-512-2921 or 1-412-317-6671 (international), using Conference ID 11161556. The rebroadcast runs from 11:00 a.m. CDT on May 6, 2026, through 11:00 p.m. CDT on June 6, 2026.

What This Might Portend for the Sector and Peers

For the sector, Bio-Techne’s quarter underscores a familiar dynamic: a steady drumbeat from large, well-financed pharma customers can buoy earnings even as biotech funding cycles remain uneven. The 2% organic revenue decline highlights sensitivity to clinical-stage spending and macro elements, while currency tailwinds provide a helpful offset. The standout growth in GMP proteins and the mid-teens lift in Spatial Biology suggest a continued push into high-value platforms—areas that peers with similar product lines may seek to double down on. Investors should watch how the company translates these platform wins into sustained top-line growth and whether the broader life sciences equipment and reagents group can translate portfolio mix into a steadier EPS trajectory, particularly if the EPS consensus nudges higher or if the revenue forecast tightens or expands with currency effects and held-for-sale impacts fading.

Notes for Investors

As with most corporate disclosures, the emphasis is on the headline numbers—EPS, revenue, and the trajectory implied by growth vectors—while the full set of footnotes and reconciliation figures will matter for modeling. The absence of a highlighted earnings surprise in this excerpt suggests the quarter lands within the range that analysts might have penciled in, though the release does not quote a specific EPS consensus figure. This makes the near-term earnings forecast and the sensitivity to foreign exchange and held-for-sale adjustments key inputs for the stock’s next leg.